Tiotropium

Generic Name
Tiotropium
Brand Names
Inspiolto Respimat, Spiriva, Spiriva Respimat, Stiolto
Drug Type
Small Molecule
Chemical Formula
C19H22NO4S2
CAS Number
186691-13-4
Unique Ingredient Identifier
0EB439235F
Background

Tiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma. Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.
...

Indication

Tiotropium powder for inhalation is indicated for the maintenance of bronchospasm in COPD and to prevent exacerbations of COPD. A combination tiotropium and olodaterol metered inhalation spray is indicated for maintenance of COPD. A tiotropium inhalation spray is indicated for the maintenance of bronchospasm in COPD, to prevent exacerbations of COPD, and to ...

Associated Conditions
Asthma, Bronchitis, Bronchoconstriction, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Exacerbation of COPD
Associated Therapies
-
Clinical Trials
Related News
prnewswire.com
·

Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a Significant Shift

FDA expands DUPIXENT use for COPD, offering new treatment options for patients. COPD affects 44 million in 7MM, with cases expected to rise. DUPIXENT targets IL-4 and IL-13 pathways, reducing exacerbations and improving lung function.
ndtvprofit.com
·

Lupin Bets On Respiratory, Injectables To Sustain Growth, Margins In US Market

Swaminathan highlights Q2 results driven by new launches, particularly Mirabegron in the US market, contributing to improved gross margins. The company is generating $220-230 million, with Mirabegron and respiratory products performing well.
business-standard.com
·

Pharma stocks: Nomura gives 'Buy' to Lupin remains 'Neutral' on others

Indian pharma giants focus on quality over quantity, with complex product filings increasing. US generics sales show slight growth, and regulatory challenges ease. Nomura recommends Lupin for its upcoming launches and stable market shares, while noting setbacks. Sun Pharma's specialty segment growth slows, and Dr Reddy's faces market share declines. Cipla and Zydus Lifesciences show growth but face inspection and competition challenges.
seekingalpha.com
·

Verona Pharma: A Post FDA Approval Analysis (NASDAQ:VRNA)

Verona Pharma's Ensifentrine (Ohtuvayre) received FDA approval for COPD in June, leading to a stock surge. The company plans to launch Ensifentrine this quarter at $2,950/month, targeting additional respiratory diseases. Analysts maintain Buy ratings with price targets of $34-$37/share. Verona ended H1 2024 with $400M in cash, aiming to fund operations beyond 2026. The stock is up 90% since approval, but the company is years from profitability. The focus is on high-volume prescribers and Medicare/insurance approvals.
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy